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Capsular polysaccharides have been confirmed to be an import-
ant virulence trait in many gram-positive and gram-negative 
bacteria. Similarly, they are proposed to be virulence traits in 
minimal Mycoplasma that cause disease in humans and ani-
mals. In the current study, goats were infected with the caprine 
pathogen Mycoplasma mycoides subsp. capri or an engineered 
mutant lacking the capsular polysaccharide, galactofuranose. 
Goats infected with the mutant strain showed only transient 
fever. In contrast, 5 of 8 goats infected with the parental strain 
reached end-point criteria after infection. These findings con-
firm that galactofuranose is a virulence factor in M. mycoides.
Keywords. Mycoplasma mycoides; M.  mycoides subsp. 
capri, carbohydrate; glycan; galactofuranose; virulence factor; 
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Mycoplasma species are economically important pathogens, 
especially in the veterinary sector. However, the mechanisms 
driving their pathogenicity and specifically their virulence traits 
remain largely speculative and based on in vitro data. Most 
available Mycoplasma vaccines have shortcomings, such as low 
efficacy and short duration of immunity. The development of 
next generation Mycoplasma vaccines will benefit greatly from 
knowledge of host-pathogen interactions. Capsular polysaccha-
rides (CPSs) have been proposed as possible Mycoplasma viru-
lence factors for >40 years [1]. They are at the interface between 
the bacterium and its host and constitute the first line of defense 
against the immune system. 
Based on in vitro experiments, it has been suggested that the 
Mycoplasma gallisepticum capsule is involved in adhesion and 
virulence [2], the exopolysaccharides of Mycoplasma pulmonis 
protect against the complement system [3], CPS of Mycoplasma 
dispar down-regulates macrophage function [4], and purified 
CPS of Mycoplasma ovipneumoniae induces an inflammatory re-
sponse through Toll-like receptor signaling in airway epithelial 
cells [5]. The exopolysaccharides of members of the “Mycoplasma 
mycoides cluster” have been characterized [6] and free CPS of 
M. mycoides induces the production of interleukin 10 in bovine 
macrophages, which acts as an anti-inflammatory [7].
Schieck et al [8], using synthetic biology tools, have shown 
that the CPS of M. mycoides subsp. capri modulates host-patho-
gen interactions in vitro. In the current study, we tested whether 
the CPS of M.  mycoides constitutes a virulence trait. Using a 
caprine challenge model, we compared the outcomes of exper-
imental infections with a highly virulent M.  mycoides subsp. 
capri strain (GM12::YCpMmyc1.1) or its CPS-lacking mutant 
derivative (GM12::YCpMmyc1.1-Δglf). Goats were infected 
with either strain, and clinical parameters and pathomorpho-
logical changes were evaluated. Attenuation was shown for 
GM12::YCpMmyc1.1-Δglf, demonstrating a role of CPS as a 
virulence factor for this important group of mycoplasmas.
METHODS
Mycoplasma Strains
In the current study, we used Mycoplasma mycoides subsp. 
capri GM12 and its derivatives GM12::YCpMmyc1.1 [9] and 
GM12::YCpMmyc1.1-Δglf [8]. Strains were cultivated at 37°C 
in Difco™ PPLO Broth (Catalogue No. 255420)  supplemented 
with 20% heat-inactivated horse serum (Sigma; catalogue No. 
H1138) 0.5% glucose, 0.03% penicillin G, 0.5 g/L thallium ace-
tate and 0.9  g/L yeast extract to early logarithmic phase, ali-
quoted and stored at −80°C. Immediately before infection, the 
vials were thawed and the concentration of Mycoplasma was 
adjusted to 108 or 109 colony-forming units (CFUs)/mL using 
broth culture medium. Bacterial concentrations were con-
firmed using the 10-fold titration method followed by plating 
on Difco™ PPLO Agar supplemented as above for quantifying 
CFUs per milliliter, using 2 aliquots for each strain.
Animal Experiment Setup
All protocols in the current study were designed and performed 
in strict accordance with Kenyan and American laws concern-
ing animal experimentation and were approved by the institu-
tional animal care and use committees at both institutions (J. 
Craig Venter Institute and International Livestock Research 
Institute [ILRI]; Institutional Animal Care and Use Committee 
reference 2016.06). Sixteen male outbred goats (Capra aega-
grus hircus), 1–2 years of age and randomly selected at the ILRI 
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ranch (Kapiti) east of Nairobi, were transferred to the ILRI 
campus in Nairobi and kept under quarantine for 2  months. 
After arrival at the campus, all goats were dewormed twice with 
levamisole and treated prophylactically with imidocarb to pre-
vent babesiosis and anaplasmosis. They were vaccinated against 
anthrax and blackleg (Blanthax; Cooper), foot-and-mouth dis-
ease (FOTIVAX™; Kevevapi), and Peste des Petits Ruminants 
(live attenuated strain Nigeria 75/1). All animals tested nega-
tive for antibodies against contagious caprine pleuropneumonia 
(CCPP), using a competitive enzyme-linked immunosorbent 
assay (IDEXX Laboratories). 
Two weeks before experimental infection, all animals were 
transferred to the animal biosafety level 2 unit. They were 
allowed to move freely within the unit, had ad libitum access 
to water and hay, and received additional pellets each morn-
ing. Three veterinarians monitored the animals’ health status 
throughout the experiment. Rectal temperature, oxygen blood 
saturation, pulse rate, and respiration rate were measured daily 
in the morning hours, using a GLA M750 thermometer (GLA 
Agricultural Electronics), VE-H100B oximeter (Edan), and a 
Littmann Classic II stethoscope, respectively. All animals were 
observed for at least 20 minutes thrice daily, and behavioral 
observations were recorded throughout the study. They were 
weighed and venous blood samples were obtained thrice weekly, 
and nasal swab samples (Flocked swabs; Copan) were obtained 
twice weekly. Swab samples were transferred into cryotubes 
filled with media and stored at −80°C until further processing. 
On the day of infection, the 2 groups were inoculated transtra-
cheally by needle puncture 5–10 cm distal of the larynx with 
108 CFUs of the respective strains M.  mycoides subsp. capri 
GM12::YCpMmyc1.1 and GM12::YCpMmyc1.1-Δglf. 
Seven days after infection, the goats were given a booster 
infection of 109 CFUs of the respective strain transtracheally. 
Animals were euthanized if they had a rectal temperature of 
>40.5°C for >3 consecutive days, moderate to severe pain or 
distress, weight loss >10% within 7 days, or a respiration rate 
>50/min for >3 days. The remaining animals in the group that 
had received M.  mycoides subsp. capri GM12 YCpMmyc1.1 
were euthanized at 35  days after infection. All 8 animals in 
the group that had received M.  mycoides subsp. capri GM12 
YCpMmyc1.1-Δglf were challenged by 109 CFUs of M. mycoides 
subsp. capri GM12 at 35  days after infection transtracheally. 
Monitoring and sampling continued as described above for up 
to 63  days after infection, when the remaining animals were 
euthanized. Euthanasia was performed by intravenous injection 
of Lethabarb Euthanasia Injection (Virbac) (200  mg/kg body 
weight).
Pathomorphological and Histological Analysis
A complete necropsy was performed on all animals. Tissue 
samples were fixed in 10% buffered formalin for 72 hours and 
subsequently processed routinely for paraffin embedding. 
Tissue was cut in 3-µm sections, which were stained routinely 
with hematoxylin-eosin and evaluated by a board-certified 
pathologist (H.P).
Microbiology
Venous blood samples, lung samples, carpal joint fluid, and pleu-
ral fluid specimens were subjected to isolation of Mycoplasma, 
as described elsewhere [10], using Mycoplasma Liquid Medium 
(Mycoplasma Experience LTD). Lung samples and pleural fluid 
were screened for Pasteurella spp. and Mannheimia spp. using 
standard methods [11].
Statistical Analysis
Log-rank (Mantel-Cox) tests were performed to determine P 
values for survival rates of the 2 groups, comparing their reach-
ing of end-point criteria; GraphPad Prism software was used 
(version 7.0d).
RESULTS
Galactofuranose as a Virulence Factor
Two groups of 8 animals each were inoculated with 
either GM12::YCpMmyc1.1-Δglf or its parental strain 
GM12::YCpMmyc1.1. Three days after infection, 1 animal 
(CM154) in the group receiving GM12::YCpMmyc1.1 pre-
sented with moderate pyrexia (>39.5°C to 40.5°C), followed by 
5 additional animals within the next 10 days (CM158, CM159, 
CM181, CM191, and CM197). All of these animals except 1 
(CM191) had severe pyrexia (body temperature, >40.5°C) on 
at least 1 day. Two of them (CM154 and CM158) had severe 
pyrexia for >3 consecutive days, which had been defined as an 
end-point criterion. Depression and anorexia were observed in 
the animals. Two in this group were euthanized because they 
had lost >10% of their body weight within 7 days, and 5 showed 
signs of depression. Severe arthritis developed in 1 animal 
(CM181) in the GM12::YCpMmyc1.1 group, which was also 
euthanized. The 3 animals that did not reach end-point crite-
ria showed various clinical signs, such as fever and depression 
(Table 1), and were euthanized at 35 days after infection. The 
animals in this group had the same lesions (Supplementary 
Table 1) seen in another caprine challenge experiment using 
GM12 (J. J.  et  al, unpublished findings), except for animal 
CM181, which also showed arthritic lesions (Table 1).
In the GM12::YCpMmyc1.1-Δglf group, the clinical picture 
was very different. Only 3 animals (CK044, CM122, and CM157) 
presented with moderate pyrexia during the follow-up period, 
and none with severe pyrexia. Coughing and nasal discharge 
were observed sporadically in both groups (Table 1). Respiration 
and pulse rates remained within the normal range throughout 
the study, although the latter was slightly higher as the animals 
entered the facilities and stabilized during the acclimatization 
week before infection. In total, 5 animals in the group infected 
with GM12::YCpMmyc1.1 reached end-point criteria and 
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were euthanized. In contrast, none of the animals in the group 
infected with GM12::YCpMmyc1.1-Δglf reached end-point 
criteria (Figure 1). This difference was significant (P  =  .005), 
which shows that the mutant strain GM12::YCpMmyc1.1-
Δglf is significantly attenuated. Therefore, we conclude that 
galactofuranose, present in the GM12::YCpMmyc1.1 but ab-
sent in GM12::YCpMmyc1.1-Δglf, contributes to virulence in 
M. mycoides subsp. capri in vivo.
Insufficient Protective Immune Response Induced by GM12::YCpMmyc1.1-
Δglf Infection 
Because the clinical outcome of the infection differed signif-
icantly between the 2 groups of animals, we challenged the 
animals that received GM12::YCpMmyc1.1-Δglf to deter-
mine whether their infection induced a protective immune 
response. These animals were subjected to a homologous chal-
lenge 35 days after infection by transtracheal inoculation with 
Table 1. Clinical Observations 0–35 Days After Infection for the Group of Animals Receiving the Parental Strain GM12::YCpMmyc1.1a
Animal No.
Time After Infection, d
Bacteremia Depression, High Fever Peaksb Arthritis Euthanasiac
CK045 NO NO NO NO No
CM047 NO NO NO NO No
CM154 7 (103 CFUs/mL) 4–8 5–8 NO 8 
CM158 7 (102 CFUs/mL) 7–9 6–9 NO 9 
CM159 NO 8–10 9 NO 13 
CM181 NO 8, 13, 19 12 18–20 20 
CM191 NO NO NO 14 No
CM197 11 (102 CFUs/mL) 9–12 11 NO 12 
Abbreviations: CFUs, colony-forming units; NO, not observed.
aFindings for animals infected with the strain GM12::YCpMmyc1.1-Δglf are not displayed because that group did not show the clinical observations listed here.
bHigh fever peaks were defined as rectal temperatures >40.5°C.
cIn animal euthanized before the end of the study (<35 days after infection).
†
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Figure 1. A, B, Setup of the in vivo trial. Two groups of outbred goats were infected with either GM12::YCpMmyc1.1-Δglf (A) or GM12::YCpMmyc1.1 (B) on the day of 
infection (day 0) and 7 days after infection. The group receiving GM12::YCpMmyc1.1 (B) was euthanized after reaching the end-point criteria or at 35 days after infection, if the 
did criteria were not reached. The other group (A) was challenged with GM12 at 35 days after infection. Abbreviations: CFUs, colony-forming units; M. mycoides, Mycoplasma 
mycoides. C, Survival rates. The P value represents the difference between the groups in reaching end-point criteria, determined using the log-rank (Mantel-Cox) test.
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M.  mycoides subsp. capri GM12. In 5 of the 8 animals severe 
disease developed that required euthanasia between 39 and 
42 days after infection; the severe disease included severe py-
rexia, depression, and arthritis (Supplementary Table 2).
Isolation of Mycoplasma
We have been able to isolate M.  mycoides subsp. capri 
GM12::YCpMmyc1.1 in blood samples from animals CM154, 
CM158, and CM197, coinciding with severe pyrexia. Therefore, 
we inoculated serial dilutions of blood in liquid medium and 
confirmed the presence of the different strains using poly-
merase chain reaction (Supplementary Table 2). Bacterial titers 
ranged between 100 and 1000 CFUs/mL (Table 1). In contrast, 
we could not isolate GM12::YCpMmyc1.1-Δglf from any of the 
8 animals inoculated with this mutant strain. However, GM12 
was isolated in blood samples from the 3 animals that died 
39–42 days after infection because of the homologous challenge 
with GM12 at 35  days after infection. Bacterial titers ranged 
between 104 and 1010 CFUs/mL (Supplementary Table 2).
DISCUSSION
The aim of the current study was to test the hypothesis that CPS 
in Mycoplasma is a virulence factor. Therefore, we took advan-
tage of M. mycoides subsp. capri, which is amenable to precise 
genetic modification and has an infection model using its native 
host (J. J. et al, unpublished findings), to determine unambig-
uously the role of CPS in virulence in vivo. The results of this 
infection trial convincingly support the initial hypothesis that 
CPS is a virulence factor. None of the animals infected with the 
glf mutant (galactofuranose deficient) showed any clinical char-
acteristics of severe disease, whereas 5 of the 8 infected with the 
parental strain GM12::YCpMmyc1.1 reached end-point criteria 
and were euthanized. In another animal trial, using 109 CFUs 
of the M. mycoides subsp. capri GM12, the morbidity rate was 
100%, and 100% of animals reached end-point criteria within 
6 days after infection (J. J. et al, submitted). 
It should be noted that the clinical picture of the group receiv-
ing GM12::YCpMmyc1.1 slightly differed from that of the group 
receiving GM12. This difference might be attributed to the dif-
ferent mode of infection represented by a superinfection or by 
the impact of integration of the YCp plasmid into the genome of 
GM12, though the latter possibility seems unlikely. Indeed, given 
the in vitro data Schieck et al [8] provided as part of the charac-
terization of the mutant GM12::YCpMmyc1.1-Δglf, it cannot be 
ruled out that the slower growth time of the mutant strain was 
partly responsible for better bacterial clearance via the innate 
immune system. However, many highly virulent Mycoplasma 
species  of the M.  mycoides cluster [12], such as Mycoplasma 
capricolum subsp. capripneumoniae and M.  mycoides subsp. 
mycoides have doubling times much longer than that of the 
mutant strain.
We tested whether the infection with the attenuated strain 
induced a protective immune response by conducting a homol-
ogous challenge. Only 3 of 8 animals, previously infected with 
the GM12::YCpMmyc1.1-Δglf and challenged with the GM12 
strain, did not reach end-point criteria. This implies an insuffi-
cient immune response.
Our study findings encourage the development of a glyco-
conjugated vaccine for Mycoplasma. Initial data on a glycocon-
jugated vaccine approach for M. mycoides subsp. mycoides show 
some good prospects and support our findings [13]. The import-
ant role of CPS in M. mycoides requires further investigation as 
to exactly how this bacterium uses its enzymatic machinery as a 
virulence trait to identify key components that can be targeted 
for the rational design of efficient subunit vaccines.
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